FindTrial
Sign In

Effects of ginger on cardiovascular risk factors in peritoneal dialysis patients

Effects of ginger on serum concentrations of advanced glycosylation end products, oxidative stress, systemic and vascular inflammatory markers and lipoprotein (a) in peritoneal dialysis patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201312062716N2
Enrollment
34
Registered
2013-12-20
Start date
2013-11-11
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiovascular risk factors in peritoneal dialysis.

Interventions

Intervention 1: Intervention: ginger supplement, Zintoma capsule, Gol-Daru Company. The patients in supplement group received 1000 mg ginger (as 4 capsules) daily for 10 weeks. Intervention 2: Con
Treatment - Drugs
Placebo
Intervention: ginger supplement, Zintoma capsule, Gol-Daru Company. The patients in supplement group received 1000 mg ginger (as 4 capsules) daily for 10 weeks.
Control: placebo containing starch, Gol-Daru Company. The patients in the placebol group recieved daily 4 placebo capsules for 10 weeks

Sponsors

National Nutrition and Food Technology Research Institute
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criterion: Continuous Ambulatory Peritoneal Dialysis for 6 months or more. Exclusion criteria: infections; inflammatory diseases; thyroid disorders; gastrointestinal diseases; receiving anti-inflammatory drugs, thyroxine, warfarin, vitamins B6, E, C, and Omega-3 fatty acids supplement.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Malondialdehyde. Timepoint: Baseline and Week 10. Method of measurement: enzyme-linked immunosorbent assay (ELISA).—

Secondary

MeasureTime frame
Serum pentosidine, carboxymethyl lysine, hs-CRP, IL-6, sICAM-1, sVCAM-1, TG, TC, LDL-C, HDL-C, apo AI, apo B100, Lp(a). Timepoint: Baseline and Week10. Method of measurement: ELISA & Enzymatic method.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hadi Tabibi

Department of Clinical Nutrition & Dietetics, Faculty of Nutrition and Food Technology, Shahid Behes

hadtabibi@yahoo.com+98 21 2207 7424

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026